Investigation of the Effects of High-Intensity Interval Exercise and Moderate-Intensity Continuous Exercise on Limb Volume, Functional Capacity, and Quality of Life in Patients With Lipedema

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorMarmara University

About this trial

This randomized controlled clinical study aims to investigate and compare the effects of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT), when combined with intermittent pneumatic compression (IPC) therapy, on limb volume, functional capacity, pain, fatigue, anxiety, depression, sleep quality, and quality of life in women with lipedema.

Lipedema is a chronic, progressive adipose tissue disorder primarily affecting women, characterized by abnormal and symmetrical fat accumulation in the lower extremities that does not improve with weight loss or limb elevation. It is often misdiagnosed as obesity or lymphedema, leading to delayed treatment. Lipedema causes pain, swelling, bruising, mobility limitation, and reduced quality of life.

Conservative treatment options include compression therapy, manual lymphatic drainage, and exercise. IPC is a non-invasive treatment used to reduce limb volume and pain while improving function and quality of life. Exercise is also a cornerstone of conservative management, but the optimal exercise intensity for lipedema remains unclear.

In this study, 69 female patients aged 18-65 years diagnosed with lipedema according to Halk and Damstra criteria will be randomly assigned into three groups:

IPC + Home-based walking program

IPC + High-Intensity Interval Training (HIIT)

IPC + Moderate-Intensity Continuous Training (MICT)

All participants will receive 15 IPC sessions (3 times per week for 5 weeks). The exercise programs (HIIT or MICT) will continue for 10 weeks, supervised by a physiotherapist. The home-based group will be encouraged to walk ≥10,000 steps daily using a pedometer application.

Primary outcome: Change in limb volume measured by circumferential measurements and the truncated cone formula.

Secondary outcomes: Pain (VAS), functional capacity (6-Minute Walk Test), muscle strength (dynamometry), pressure pain threshold (algometry), physical activity (IPAQ-SF), lower extremity function (LEFS), quality of life (SF-12), sleep quality (PSQI), fatigue (FSS), and anxiety/depression (HADS).

Measurements will be taken at baseline (T0), after 15 IPC sessions (T1), and after 30 total sessions or 10 weeks (T2).

The investigators hypothesize that both HIIT and MICT combined with IPC will provide superior improvements in physical and psychological outcomes compared to IPC with a home-based walking program alone.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female participants aged 18-65 years

Able to read and write (literate)

Clinically diagnosed with lipedema according to Halk and Damstra criteria

Disqualifiers

Pregnancy or breastfeeding

Illiteracy

Refusal or inability to provide written/signed consent

Lower extremity fracture, trauma, or surgery within the past 12 months

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intermittent Pneumatic Compression (IPC)

    Device

    Applied to both lower limbs for 30 minutes at 50 mmHg, 3 times per week for 5 weeks using DoctorLife LX7 Max device. Used in all study arms.

  • Home-Based Walking Program

    Behavioral

    Participants perform ≥10,000 steps/day using PACER pedometer app; encouraged through exercise logs and follow-up.

  • High-Intensity Interval Training (HIIT)

    Behavioral

    Supervised cycling-based interval exercise, 3×/week for 10 weeks, individualized by GCT-TT protocol.

  • Moderate-Intensity Continuous Training (MICT)

    Behavioral

    Supervised continuous cycling exercise, 3×/week for 10 weeks, at 50% GCT-TT power output.

Treatment groups

69 Participants
are divided into 3 treatment groups
Group A: Intermittent Pneumatic Compression + Home-Based Walking ProgramExperimental treatment 2 interventions
Group B: Intermittent Pneumatic Compression + High-Intensity Interval Training (HIIT)Experimental treatment 2 interventions
Group C: Intermittent Pneumatic Compression + Moderate-Intensity Continuous Training (MICT)Experimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Change in Lower Extremity Volume (mL)

Lower limb volume will be calculated using circumferential measurements taken every 8 cm along both legs in the standing position. Volumetric values will be derived using the truncated cone formula. The primary endpoint is the change in total limb volume from baseline to week 10. Measurements will be conducted by a blinded assessor.

Time frame
Baseline (Day 1), after 15 IPC sessions (Day 36), and post-intervention (Day 71)

Secondary outcomes

1

Change in Functional Exercise Capacity (6-Minute Walk Test Distance, meters)

The 6-Minute Walk Test measures the distance a participant can walk on a flat surface in six minutes. It reflects overall functional capacity and endurance. The change from baseline to week 10 will be compared between groups.

Time frame
Baseline (Day 0), end of week 5 (Day 36), and end of week 10 (Day 71)
2

Change in Physical Activity Level (International Physical Activity Questionnaire-Short Form; MET-min/week)

The IPAQ-SF assesses physical activity intensity and duration. Higher scores indicate greater activity level.

Time frame
Baseline (Day 0), and end of week 10 (Day 71)
3

Change in Fatigue Severity (Fatigue Severity Scale, FSS; 9-63)

The FSS measures the impact of fatigue on daily functioning. Scores ≥36 indicate severe fatigue. Lower post-treatment scores indicate improvement.

Time frame
Baseline (Day 0), end of week 5 (Day 36), and end of week 10 (Day 71)
4

Change in Quality of Life (SF-12 Physical and Mental Composite Scores)

The SF-12 questionnaire evaluates physical and mental components of quality of life. Higher scores represent better health-related quality of life.

Time frame
Baseline (Day 0), end of week 5 (Day 36), and end of week 10 (Day 71)

Other outcomes

1

Adherence to Exercise and Treatment Program

Measured as the percentage of attended exercise sessions (out of 30 planned) and mean daily step count from pedometer data in the home-based walking group. Used to assess adherence and compliance.

Time frame
Throughout the 10-week intervention period; summarized at post-intervention (Day 71)
2

Adverse Events and Cardiovascular Safety

Monitoring of adverse events during IPC or exercise sessions, including vital signs (heart rate, rhythm, oxygen saturation, and blood pressure) recorded each session.

Time frame
Throughout the 10-week intervention period; summarized at post-intervention (Day 71)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: